Literature DB >> 33554530

Chest pain management: use of troponins in internal medicine wards.

Alfonso Ilardi1, Giuseppe Caruso2, Ciro Rosario Ilardi3, Maria D'Avino4.   

Abstract

OBJECTIVES: To probe the reference biomarkers used to manage chest pain (CP) by Italian internists.
METHODS: Two hundred and fifty-seven doctors registered as members of the Federation of Associations of Hospital Doctors on Internal Medicine of the Campania Region (FADOI-Campania) were surveyed by means of Google Forms platform. Each participant was asked to report his/her sex, age, and location and hospital size (beds in hospital) in which he/she worked. Furthermore, they were asked to indicate the reference biomarker he/she usually employed in the management of patients with CP, choosing from four possible answers. In line with national and international guidelines, cardiac troponins are the gold standard biomarkers.
RESULTS: Eighty-two internists (30 females) completed the survey. Interestingly, only 30.5% of participants indicated the cardiac troponins as reference biomarker. Moreover, internists working in medium-sized hospitals appeared to prefer the simultaneous measurement of cardiac troponins and Creatine Kinase MB Isoenzyme.
CONCLUSIONS: Given the economic impact of performing inappropriate examinations and the frequency of the CP symptom and associated diseases, rethinking pathways in a multidisciplinary and shared fashion can promote optimization and appropriateness, and therefore stop wastefulness.
© 2020 Alfonso Ilardi et al., published by De Gruyter, Berlin/Boston.

Entities:  

Keywords:  chest pain; internal medicine; survey; troponins

Year:  2020        PMID: 33554530     DOI: 10.1515/dx-2020-0133

Source DB:  PubMed          Journal:  Diagnosis (Berl)        ISSN: 2194-802X


  1 in total

1.  Psychometric properties of the STAI-Y scales and normative data in an Italian elderly population.

Authors:  Ciro Rosario Ilardi; Nadia Gamboz; Alessandro Iavarone; Sergio Chieffi; Maria Antonella Brandimonte
Journal:  Aging Clin Exp Res       Date:  2021-03-17       Impact factor: 3.636

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.